Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last SFr.272.75 CHF
Change Today +0.25 / 0.09%
Volume 24.7K
RO On Other Exchanges
Symbol
Exchange
OTC US
Xetra
SIX Swiss Ex
SIX Swiss Ex
Mexico
Frankfurt
As of 11:43 AM 06/3/15 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-br (RO) Snapshot

Open
SFr.272.50
Previous Close
SFr.272.50
Day High
SFr.273.25
Day Low
SFr.270.50
52 Week High
12/3/14 - SFr.290.00
52 Week Low
01/16/15 - SFr.240.00
Market Cap
238.0B
Average Volume 10 Days
24.0K
EPS TTM
SFr.10.99
Shares Outstanding
160.0M
EX-Date
03/5/15
P/E TM
24.8x
Dividend
SFr.8.00
Dividend Yield
2.93%
Current Stock Chart for ROCHE HOLDING AG-BR (RO)

roche holding ag-br (RO) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Europe, North America, and Asia. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, drug metabolism disorder, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, human papillomavirus, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and west nile virus diseases. The company also provides diagnostic solutions for blood gas analysis; blood screening; cancer screening; cardiac markers; cardiovascular testing; cholesterol monitoring; coagulation monitoring, routing, and specialty testing; data management; diabetes monitoring and therapy; electrolytes analysis; emergency medicine; hemostasis; heterogeneous immunochemistry; homogenous immune assays; immunology; infectious diseases; intensive care testing; microarray; neonatal intensive care units; nucleic acid purification; PCR clinical diagnostics; pharmacogenomics; physical fitness and platelet function testing; PCR diagnostic systems; serum work area; urinalysis; and workflow solutions. In addition, it offers products for researchers, such as amplification, cell analysis, gene expression, gene knockdown, genome sequencing, microarrays, nucleic acid purification, protein analysis, PCR systems, and transfection products. The company has collaboration agreements with AmorChem, AbbVie, Xenon Pharmaceuticals, Stratos Genomics, The Garvan Institute, Cornell University, and University of Washington. The company was founded in 1896 and is headquartered in Basel, Switzerland.

88,509 Employees
Last Reported Date: 01/28/15
Founded in 1896

roche holding ag-br (RO) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.3M
Chief Financial Officer and IT Officer
Total Annual Compensation: SFr.4.1M
Chief Operating Officer of Pharmaceuticals di...
Total Annual Compensation: SFr.5.0M
Chief Operating Officer of Diagnostics Divisi...
Total Annual Compensation: SFr.2.5M
General Counsel and Corporate Secretary
Total Annual Compensation: SFr.2.8M
Compensation as of Fiscal Year 2014.

roche holding ag-br (RO) Key Developments

Amgen Announces Collaboration with Roche on Cancer Immunotherapy Study with Investigational Medicines Talimogene Laherparepvec and Atezolizumab

Amgen announced a collaboration with Roche on a Phase 1b study to evaluate the safety and efficacy of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with Roche's investigational anti-PDL1 therapy, atezolizumab (also known as MPDL3280A), in patients with triple-negative breast cancer and colorectal cancer with liver metastases. Talimogene laherparepvec is an investigational oncolytic immunotherapy designed to selectively replicate in tumors (but not normal tissue) and to initiate an immune response to target cancer cells. Atezolizumab is an investigational monoclonal antibody designed to interfere with the PD-L1 protein. The rationale for combining these two investigational agents is to activate an anti-tumor immune response with talimogene laherparepvec and to block inhibitory T cell checkpoints with atezolizumab, to potentially increase the anti-tumor activity relative to each agent alone.

Roche Holding Reportedly Mulls Acquisitions

Roche Holding AG (SWX:ROG) is reportedly considering acquisitions in the areas of orphan drugs and diagnostics products.

Roche Reports Positive Phase III Data for Gazyvaro in Indolent Non-Hodgkin's Lymphoma

Roche has reported positive results from its Phase III GADOLIN study assessing Gazyva/Gazyvaro (obinutuzumab) in combination with bendamustine followed by Gazyva/Gazyvaro in people with indolent non-Hodgkin's lymphoma (NHL) that is refractory to treatment based on MabThera/Rituxan (rituximab). In particular, the study demonstrated that a combination of Gazyva/Gazyvaro and bendamustine followed by Gazyva/Gazyvaro alone associated with a 45% reduction in the risk of disease worsening or death (progression-free survival; PFS) versus bendamustine alone. According to investigator review, the median PFS of Gazyva/Gazyvaro treatment was 29.2 months, compared with 14.0 months for bendamustine alone. The study was stopped ahead of its protocol-specified final analysis as a result of the high level of benefit observed. Subject to positive regulatory decisions, it would expand the indications that the treatment has been approved for, with Gazyva/Gazyvaro in combination with chlorambucil having already received approval in over 50 countries for previously untreated chronic lymphocytic leukaemia. Gazyvaro is also being assessed versus a combination of MabThera/Rituxan and chemotherapy in the Phase III GOYA study for first-line diffuse large B-cell lymphoma and a combination of MabThera/Rituxan and chemotherapy in the Phase III GALLIUM study in first-line indolent NHL. The GADOLIN study was a Phase III, open-label, multi-centre, randomised two-arm study that involved 413 patients and assessed Gazyva/Gazyvaro in combination with bendamustine followed by Gazyva/Gazyvaro alone for up to two years, versus bendamustine alone.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RO:SW SFr.272.75 CHF +0.25

RO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $114.65 USD +0.71
Johnson & Johnson $100.09 USD +0.11
Novartis AG SFr.97.00 CHF +0.70
Pfizer Inc $34.41 USD -0.08
Sanofi €91.12 EUR +1.48
View Industry Companies
 

Industry Analysis

RO

Industry Average

Valuation RO Industry Range
Price/Earnings 27.1x
Price/Sales 5.0x
Price/Book 12.7x
Price/Cash Flow 22.1x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-BR, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.